Target intelligence / Profile preview

B-cell receptor specific for Yersinia pestis F1 and V antigens (BCR-F1/V)

Target
BCR-F1/V
Molecular classification
Receptor, Immunoglobulin family
01

Overview

B-cell receptors (BCRs) specific for F1 and V epitopes are specialized membrane-bound immunoglobulins on B-lymphocytes that recognize the Fraction 1 (F1) capsular protein and the LcrV (V) antigen of Yersinia pestis, the causative agent of plague (Smiley, 2008). The F1 antigen is a structural protein that forms the bacterial capsule, which is essential for resisting phagocytosis by host macrophages, while the V antigen is a critical regulatory component of the Type III secretion system (T3SS) that facilitates the injection of effector proteins into host cells and modulates the host immune response by inducing immunosuppressive cytokines (Heath et al., 1998). These BCRs serve as the primary recognition sites for recombinant vaccines, such as the rF1-V fusion protein, which are designed to elicit a robust and protective humoral immune response (Quenee et al., 2008). Upon binding their respective epitopes, these receptors trigger signal transduction pathways that lead to B-cell proliferation and the secretion of high-affinity antibodies. These antibodies provide protection by neutralizing the pathogen's virulence factors, opsonizing the bacteria for clearance, and blocking the function of the T3SS, which is vital for the pathogen's survival and pathogenesis within the host.

Other names
Anti-F1/V B-cell receptorYersinia pestis antigen-specific BCRF1-V specific B-lymphocyte receptorCaf1/LcrV-specific B-cell receptor
02

Mechanism of action

Binding of F1 and V antigens to these receptors induces B-cell differentiation into plasma cells that secrete neutralizing antibodies, which block bacterial adhesion, inhibit the Type III secretion system, and promote opsonophagocytosis.

03

Biological functions

Immune responseAntigen recognitionB-cell activationAntibody productionHumoral immunity
04

Disease associations

InfectionPlague (Bubonic, Pneumonic, and Septicemic)
05

Safety considerations

Limited protection against F1-negative Yersinia pestis strainsPotential for sub-protective immune responses in certain populationsRisk of vaccine-induced adverse effectsRequirement for high antibody titers to ensure survival against pneumonic challenge
06

Interacting drugs

rF1-V fusion protein vaccine

4 more in the full profile.

07

Biomarkers

Anti-F1 IgG antibody titerAnti-V IgG antibody titerF1-V specific memory B-cell frequencySerum neutralizing antibody activity

Beyond the preview

Go deeper on B-cell receptor specific for Yersinia pestis F1 and V antigens (BCR-F1/V).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on B-cell receptor specific for Yersinia pestis F1 and V antigens (BCR-F1/V).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call